Phathom Pharmaceuticals (PHAT) EBT Margin (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has 4 years of EBT Margin data on file, last reported at 50.66% in Q1 2026.

• EBT Margin for Q1 2026 came in at 50.66%, up 27997.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 76.29% (up 34615.0% YoY), and the FY2025 annual result was 126.24%, up 47884.0% from the prior year.
• EBT Margin retreated to 50.66% in Q1 2026 per PHAT's latest filing, from 36.72% in the prior quarter.
• Over five years, EBT Margin peaked at 36.72% in Q4 2025 and troughed at 11665.1% in Q4 2023.
• A 4-year average of 1868.91% and a median of 290.89% in 2025 frame the typical range for EBT Margin.
• The sharpest annual moves came in 2024 and 2025: EBT Margin jumped 1141396 bps in 2024, then jumped 21443 bps in 2025.
• A 4-year view of EBT Margin shows it stood at 11665.1% in 2023, then soared by 98 bps to 251.15% in 2024, then surged by 85 bps to 36.72% in 2025, then sank by 38 bps to 50.66% in 2026.
• Business Quant data shows PHAT's EBT Margin at 50.66% in Q1 2026, 36.72% in Q4 2025, and 60.53% in Q3 2025.